Business Wire

CA-VELODYNE-LIDAR

13.11.2020 14:02:09 CET | Business Wire | Press release

Share
Velodyne Lidar Unveils Breakthrough Solid State Sensor for Advanced Driver Assistance Systems (ADAS) and Autonomy

Velodyne Lidar, Inc. (Nasdaq: VLDR) today debuted its latest innovation in its broad array of lidar sensors, the Velarray H800. The solid state Velarray H800 is architected for automotive grade performance and built using Velodyne’s breakthrough proprietary micro-lidar array architecture (MLA). With combined long-range perception and a broad field of view, this sensor is designed for safe navigation and collision avoidance in advanced driver assistance systems (ADAS) and autonomous mobility applications. The Velarray H800’s compact, embeddable form factor is designed to fit neatly behind the windshield of a truck, bus or car, or be mounted seamlessly on the vehicle exterior. The Velarray H800 will be available at high-volume production levels with a target price of less than $500 to drive broad adoption in consumer and commercial vehicle markets.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201113005108/en/

“Velodyne’s launch of the Velarray H800 lidar sensor, which is the first in a family of solid state lidars we will be releasing publicly, is important to automakers for three reasons,” said Anand Gopalan, Velodyne Lidar CEO. “First, the Velarray H800 was specifically designed for high volume automotive applications with feedback from leading OEM customers. It uses Velodyne’s global network of high-quality manufacturing partnerships that provide the high quantity automakers need. Second, Velodyne’s proprietary technology and experience, combined with our manufacturing capacity, allow us to offer the sensor at a price that makes economic sense for automakers. Third, the world needs enhanced safety in consumer vehicles and the Velarray product line makes that available to end consumers creating safer roadways and cars for all.”

The Velarray H800 can help automakers design ADAS solutions that help reduce traffic accidents as well as injuries and deaths of drivers, passengers, bicyclists and pedestrians. The World Health Organization reports that annual deaths caused by traffic crashes have reached 1.35 million globally.

“We want to help build the public’s trust in automated vehicle systems,” Marta Hall, Velodyne founder and CMO, commented. “We believe the Velarray H800 is the first of many lidar sensors that will be used in systems for powerful vehicle safety. Velodyne is introducing it as a key sensor for systems designed as building blocks for vehicle safety. Once the public experiences the benefits of reliable automated safety systems, they will welcome more products like this. We can save lives with ADAS.”

The Velarray H800 boasts outstanding range, field of view and resolution to support advancements in autonomy and ADAS, from Level 2 to Level 5. This spans the entirety of ADAS features from Lane Keep Assist and Automated Emergency Braking, all the way to the top levels of automated driving. The compact, low cost sensor can be paired with Velodyne’s Vella software suite, enabling the full spectrum of safety features.

The efficacy of lidar in creating robust and feature-rich ADAS has been acknowledged across the auto industry in the past few years. Proprietary testing indicated superiority of the Velarray-based solution where a traditional camera and radar system failed. Please see Velodyne’s recently issued white paper regarding Pedestrian Automatic Emergency Braking (PAEB) here .

With a field of view of 120 horizontal degrees by 16 vertical degrees, the Velarray H800 allows for outstanding detection of peripheral, near-field, and overhead objects while addressing corner cases on sloping and curving roads. The Velarray H800 provides perception data at a range of up to 200 meters, supporting safe stopping distances even at highway speeds. Featuring a configurable frame rate, the Velarray H800 offers the rich point cloud density required for high resolution mapping and object classification tasks.

Drawing on insights gained from going public, Gopalan commented, “During meetings with investors over the past several months, I have received many questions about Velodyne’s solid state roadmap. The fact is that Velodyne has offered solid state lidar sensors for more than two years, but we’ve used the term ‘directional’ sensors to describe Velodyne’s solid state lidar technology. With the introduction of the Velarray H800, we saw the opportunity to demonstrate how Velodyne’s lidar technology prowess spans many form factors and applications. Velodyne wants to improve roadway safety by making all vehicles smarter. That’s why we are working so hard to provide ADAS technology that can be implemented in the marketplace now. You will soon see more of our sensors and software product releases, offering building blocks of vehicle safety for the public.”

The Velarray H800 is Velodyne’s first new sensor to be launched since the company went public on September 30, 2020. The sensor kicks off the next generation of the company’s solid state lidar portfolio. It complements and leverages Velodyne’s expertise in innovating, building and delivering lidar technology.

About Velodyne Lidar

Velodyne Lidar (NASDAQ: VLDR) ushered in a new era of autonomous technology with the invention of real-time surround view lidar sensors. Velodyne is the first public pure-play lidar company and is known worldwide for its broad portfolio of breakthrough lidar technologies. Velodyne’s revolutionary sensor and software solutions provide flexibility, quality and performance to meet the needs of a wide range of industries, including autonomous vehicles, advanced driver assistance systems (ADAS), robotics, unmanned aerial vehicles (UAV), smart cities and security. Through continuous innovation, Velodyne strives to transform lives and communities by advancing safer mobility for all. For more information, visit www.velodynelidar.com .

Forward Looking Statements

Statements in this release may contain “forward looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995 including, without limitation, all statements other than historical fact and include, without limitation, statements regarding Velodyne’s target markets, new products, development efforts, competition. When used in this press release, the words “estimates,” “projected,” “expects,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “can”, “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions) are intended to identify forward-looking statements. These forward-looking statements are not guarantees of future performance, conditions or results and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside Velodyne’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. Important factors, among others, that may affect actual results or outcomes include Velodyne’s ability to manage growth; Velodyne’s ability to execute its business plan; uncertainties related to the ability of Velodyne’s customers to commercialize their products and the ultimate market acceptance of these products; the uncertain impact of the COVID-19 pandemic on Velodyne’s and its customers’ businesses; uncertainties related to Velodyne’s estimates of the size of the markets for its products; the rate and degree of market acceptance of Velodyne’s products; the success of other competing lidar and sensor-related products and services that exist or may become available; uncertainties related to Velodyne’s current litigation and potential litigation involving Velodyne or the validity or enforceability of Velodyne’s intellectual property; and general economic and market conditions impacting demand for Velodyne’s products and services. Velodyne undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Link:

ClickThru

Social Media:

https://www.facebook.com/velodyneLiDAR/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release

A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye